| INTRODUCTION
Vedolizumab (Entyvio, Takeda Pharmaceuticals, Japan) is a monoclonal antibody (mAb) against a4b7, an integrin facilitating leucocyte migration to the gut via binding of MADCAM1 on intestinal endothelium, shown to be efficacious for (IBD) patients with moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). [1] [2] [3] [4] [5] Infliximab (Remicade, Janssen, USA) and adalimumab (Humira, Abbvie, USA) are two anti-TNFs widely used for treatment of IBD. The combination of infliximab with thiopurines has shown increased efficacy compared to infliximab alone in randomised placebo-controlled clinical trials and in real-life cohorts in both CD and UC. [6] [7] [8] Results were more mixed for combination adalimumab-thiopurines in a controlled trial and in observational studies, [9] [10] [11] possibly indicating that for both agents the benefit of concomitant thiopurines may be dependent on the clinical context in which they are given. 12 Combinations of two biological drugs, however, have been little explored. Nonetheless, the concept of combo-biologics, either in the form of co-administration of available drugs or by novel bi-specific antibodies, is increasingly gaining interest in IBD and other therapeutic areas. 13 Whether the combination of vedolizumab with anti-TNF can confer better clinical outcomes than each drug alone is yet unknown. However, concerns about combination of biologics have been raised with respect to safety issues. These not only pose an obstacle to drug development programs, but also prompt some clinicians to deliberately delay initiation of vedolizumab in patients who failed and stopped anti-TNF, despite the risk of further disease progression or steroid exposure during this imposed waiting-interval. In addition to safety, other knowledge gaps relate to possible alterations in drug pharmacokinetics when these two biologics are coadministered, or the possibility that anti-TNFs may increase the number and/or expression level of a4b7+ cells, thereby rendering patients more resistant to subsequent vedolizumab or in need of higher drug dosing.
Therefore, the aim of this study was to explore the safety, efficacy, pharmacokinetics and pharmacodynamics of vedolizumab in patients who were effectively also simultaneously co-exposed to anti-TNF.
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| Statistical analysis

| Patient population and study flow
Of 229 patients starting vedolizumab in St.Etienne and Sheba
Medical centers during the study period, 45 patients, who started vedolizumab after a recent discontinuation of adalimumab or infliximab within the pre-defined intervals, were identified. Of these, 20 patients were further excluded as they had no detectable anti-TNF drug in blood at time of the first infusion of vedolizumab.
Thus, 25 patients who were de facto co-exposed simultaneously to vedolizumab and aTNF (15 adalimumab, 10 infliximab) were included in the final analysis. These were compared in a 1:2 ratio to 50 randomly selected consecutive patients matched for disease type (CD or UC), who started vedolizumab without recent cessation of an anti-TNF, as defined above. The patient flow in the study is depicted in Figure 1 . The patients' clinical and demographic characteristics, as well as baseline laboratory parameters are shown in Table 1 . As shown in Table 1 , and as expected from the inclusion criteria, there was a higher rate of prior aTNF exposure among the VDZaTNF group compared to the VDZ one. Among the patients who were previously exposed to anti-TNFs, prior cessation of anti-TNF due to secondary loss of response was more common among VDZaTNF group. In addition, albumin levels at day 0 tended to be higher among VDZ-aTNF patients compared to VDZ ones, although the difference was not statistically significant. Nevertheless, to exclude the possibility that these co-variates may have confounded the results observed in the PK analysis, a multiple regression analysis was performed for each induction time-point to assess the independent impact on vedolizumab drug levels of pertinent factors (either differing with P<0.1 between study groups or ones previously reported to be associated with vedolizumab drug levels). As shown in Table 2 , only albumin and weight had a statistically significant independent association with some, albeit not all, vedolizumab drug levels. None of the other factors, including patients' classification to VDZ-aTNF or to VDZ groups, were independently associated with vedolizumab drug concentrations at any of the three time-points. A more conventional approach for dual-biological therapy is that of concomitant administration of two already approved biologics.
However, prior attempts have raised concerns pertaining to the safety and efficacy of this strategy. Thus, randomised placebo-controlled trials in rheumatoid arthritis patients treated with an antiTNF agent, etanercept, which tested the addition of abatacept (CTLA4-Fc fusion protein), anakinra (IL-1 receptor antagonist) or rituximab (anti-CD20) to the anti-TNF, yielded no clinical benefit and resulted in increased rate of adverse events, some of which were severe. [21] [22] [23] In IBD, only a single trial is available, in which CD patients who were partial responders to infliximab were randomised to continue infliximab maintenance therapy or to receive infliximab with natalizumab, the anti a4b1 integrin antibody. 24 Patients receiving the combination had a nonsignificant trend for greater reduction in the CDAI score compared to patients continuing infliximab alone and no increased adverse events rate was observed.
The anti-integrin vedolizumab is a gut selective antibody which is efficacious for CD and UC. The pharmacokinetics of vedolizumab have been reported in the GEMINI clinical trials and in real-life cohorts. [32] [33] [34] However, whether co-exposure to two monoclonal antibody biologics will alter their pharmacokinetics is still unknown. A recent study reported in an abstract form suggested patients recently exposed to anti-TNFs have lower vedolizumab drug levels. 35 However, no data were presented whether this finding was retained after consideration of confounders known to affect vedolizumab pharmacokinetics. In this study, there was no difference in vedolizumab drug levels at weeks 2, 6 or 14 in patients simultaneously co-exposed to anti-TNFs versus those who were not. In addition, multi-variable analyses partially reproduced previously reported association of baseline albumin and weight on vedolizumab, but did not identify an impact for co-exposure to anti-TNF.
A previous study showed anti-TNF reduces the expression of MAdCAM-1 and increases levels of circulating a4b7 integrin-positive cells in responding patients but not in nonresponders to aTNF. This observation was interpreted by some experts as possibly responsible-at least in part -for reduced rate or slower response to VDZ in anti-TNF exposed patients. 37 In this study, an exploratory analysis in a separate cohort of 12 patients starting infliximab showed a numerical trend for increased a4b7 expression on T cells after infliximab administration. When we analysed only the 10 responding patients, our observation has not changed significantly, which is in line with this prior report. 36 vedolizumab to an anti-TNF has not been explored herein and merits a separate study.
In conclusion, patients who are de facto co-exposed to anti-TNF while receiving vedolizumab induction therapy do not seem to experience higher rate of adverse events compared to patients exposed to vedolizumab alone, and have similar clinical benefit and drug concentrations. These data indicate there is probably little need for deliberate waiting-interval before starting vedolizumab in patients who recently stopped anti-TNF. They also indicate the need to further explore combination of biologics as novel treatment strategies in IBD.
